Stock Mumak

Stock Profile

Bayer

Bayer is operationally improving its earnings position. However, high debt, weak cash flow, and legal risks are slowing the stock's recovery.

Stock Snapshot

Bayer Logo
Table HeaderTable Header
CompanyBayer AG
SectorHealthcare
ThemePharma & Life Science
Business ModelDevelopment and commercialization of pharmaceuticals as well as solutions for agriculture and crop protection
ISINDE000BAY0017
Market Capitalizationapprox. EUR 47 billion
UMBRELLA StatusActive
  • Geopolitics
  • Industry
  • Fundamentals
  • Sentiment
  • Technical Analysis

Price Performance (12 Months)

Aktuelle Unternehmensmeldungen

Bayer
Healthcare

Valuation Analysis: Bayer AG

ISIN: DE000BAY0017

Bayer is gradually evolving from a burdened legal and restructuring case into a recovery story. Crop Science is increasing profitability, while Nubeqa and Kerendia are seeing strong growth in the pharmaceutical business. Furthermore, the Apollo transaction strengthens the balance sheet. However, high financial debt, negative free cash flow, and the decline in sales for Xarelto and Eylea remain central risks.
Compass 4 out of 5
Active icon
More research

Latest Portfolio Updates

MUMAK SpotLight

MUMAK SpotLight of the week: Intel becomes part of the UMBRELLA Strategy

Intel was newly added to the UMBRELLA Strategy, expanding the portfolio's semiconductor positioning. At the same time, Revolution Medicines, Bayer,
Next Update
RED HOT CHILI™ MUMAK

RED HOT CHILI™ MUMAK of the Week: No Award This Week

The RED HOT CHILI™ MUMAK will not be awarded this week.
Next Update
Revolution Medicines
Company Update

Revolution Medicines Update: FDA Breakthrough Therapy designation expands RASONQUE’s potential

Revolution Medicines receives another FDA Breakthrough Therapy designation for RASONQUE.
Next Update
Weekly Update

Weekly Market Overview – September 7-September 13, 2026

A volatile week puts the risk management of the UMBRELLA strategy in focus. Technical signals lead to targeted adjustments in
Next Update